ArticleFood science & nutrition2025
Epigallocatechin-3-Gallate Mitigates Atopic Dermatitis-Like Skin Lesions and Psychiatric Comorbidities by Reducing Oxidative Stress.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Therapeutic Potential of Polyphenols in Modulating Barrier Lipids, Microbiome Interactions, and Inflammatory Pathways in Atopic Dermatitis.Nutrients · 2026Review
- EGCG Derivatives Alleviate Diquat-Induced Liver and Gut Damage in Mice by Activating an Antioxidant Pathway and Enhancing Barrier Function.Animals : an open access journal from MDPI · 2026Article
- Epigallocatechin-3-Gallate Mitigates Atopic Dermatitis-Like Skin Lesions and Psychiatric Comorbidities by Reducing Oxidative Stress.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease often accompanied by psychiatric comorbidities like anxiety and depression, poses significant therapeutic challenges. This study aims to explore the therapeutic effects and mechanisms of dietary supplementation with epigallocatechin-3-gallate (EGCG) on AD skin lesions and comorbid anxiety/depressive disorders through in vivo and in vitro experiments. Macroscopical and histopathological evaluation revealed that gavage administration of EGCG (50 or 100 mg/kg) significantly improved AD skin lesions, as evidenced by the reduced dermatitis severity scores, TEWL value and blood flow perfusion, and diminished infiltration of inflammatory and mast cells (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.